Skip to content
Search
Please enter at least 3 characters.

Latest Stories

New RSV vaccine for pregnant women could prevent 5,000 infant hospitalisations - Study shows

New RSV vaccine for pregnant women could prevent 5,000 infant hospitalisations - Study shows

NHS England will commission 50 community pharmacies in the East of England Region to provide RSV vaccines starting September 2024 

The new Respiratory Syncytial Virus (RSV) vaccination programme launching in England this autumn is expected to prevent 5,000 hospitalisations and 15,000 emergency department attendances for infants.

Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, NHS England and the UK Health Security Agency (UKHSA) announced in June the introduction of two new free RSV vaccination programmes starting on 1 September 2024 - one targeting pregnant women and another for older adults aged 75 and over.


While these programmes will primarily be rolled out through general practice and NHS Trusts, NHSE plans to include up to 50 community pharmacies in the East of England Region to administer the vaccines.

A new study estimates that the RSV vaccination programme for pregnant women could typically prevent 5,000 hospitalisations and 15,000 emergency department attendances for infants.

With an anticipated uptake of about 60 per cent among pregnant women, the study projects that the maternal programme could result in 70,000 fewer RSV illnesses in infants under 12 months, 20,000 fewer GP consultations, and prevent over 200 infants from being admitted to intensive care units.

Similarly, it is estimates that the first season of the older adult’s catch-up programme could prevent around 2,500 hospital admissions, 15,000 GP visits and 60,000 RSV illnesses in adults in this age group.

Professor Dame Jenny Harries, Chief Executive of UKHSA, emphasised the benefits of the vaccine: “Having the vaccine during every pregnancy is the best way to protect your baby against RSV, as the vaccine boosts your immune system to produce more antibodies against the virus, and these then pass through the placenta to help protect your baby from the day they are born.”

“The vaccine reduces the risk of severe bronchiolitis by 70 per cent in the first six months of life.”

She noted that the vaccine has been approved by medicines regulators in the UK, Europe and the USA.

Andrew Gwynne, Minister for Public Health and Prevention, underscored the importance of maternal vaccinations in safeguarding newborns from life-threatening illnesses like RSV.

He shared that his grandson contracted RSV just days after birth, resulting in weeks in intensive care and persistent, long-lasting health issues.

“I wouldn’t wish that on any family. This new vaccine programme offers us an opportunity to prevent similar trauma, helping stop thousands of hospitalisations while saving precious lives,” he said.

Gwynne urged everyone eligible to get vaccinated to ensure protection from the first day of the baby’s life and safeguard the child’s future.

Steve Russell, NHS National Director for Vaccinations and Screening, encouraged pregnant women at 28 weeks or more to consult their maternity team or GP about getting vaccinated. He also urged individuals aged 75 to 79 to come forward as soon as they are invited by their GP.

RSV infects around 90 per cent of children within the first 2 years of life, but many people are unaware of it.

While the virus usually results in mild, cold-like symptoms, it can cause serious lung infections such as pneumonia and infant bronchiolitis, and is a major global cause of infant mortality.

According to UKHSA, RSV illness is the main cause of winter pressures in children’s hospitals each year, contributing to strain on pediatric intensive care units and resulting in cancelled operations.

It accounts for approximately 20,000 hospitalisations in children under one and is responsible for 20 to 30 infant deaths annually in the UK.

Professor Dame Jenny Harries stated that these two new RSV vaccine programmes offer huge opportunities to prevent severe illness in those most vulnerable to the virus, thereby helping save lives and alleviate NHS winter pressures.

“UKHSA has provided critical scientific information to evidence the benefits of a national RSV immunisation programme and so the rollout of the vaccine is a truly positive moment for the public’s health,” she said, urging all those eligible to take up the offer when the programmes begin in September.

The UKHSA noted that it is actively collaborating with NHS colleagues to ensure the effective rollout of the two new RSV vaccination programmes and will also monitor their impact through its routine national surveillance.

More For You

NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Free morning-after pill at pharmacies to end postcode lottery for patients

Pharmacy technicians will be allowed to supply of drospirenone for contraception under PGD,

gettyimages

Pharmacy contract: Free morning-after pill to be available at pharmacies soon

The UK government has announced that, for the first time ever, the ‘morning-after pill’ or emergency contraceptive pill will be available free of charge at pharmacies on the NHS, ending the postcode lottery women face in accessing the medicine and reducing inequalities.

The Department of Health and Social Care (DHSC) has confirmed a record £3.073 billion funding package for community pharmacies in 2025/26, alongside an additional £215 million to sustain Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Royal College status: The PDA calls for ‘meaningful and collaborative dialogue’

The profession’s success will depend on collaboration across all sectors, says PDA.

gettyimages

Royal College vote: Less than 7% of GB pharmacists in favour, says PDA

The Pharmacists’ Defence Association (PDA) has criticised the Royal Pharmaceutical Society (RPS) for moving too quickly to a ballot on its proposed transition to a Royal College, arguing that it resulted in low participation from pharmacists in Great Britain.

Announcing the results of the special resolution vote, the RPS said that the outcome was a “clear mandate” in favour of the transformative change.

Keep ReadingShow less
RPS Wales calls for urgent investment in pharmacy workforce at Senedd meeting

Third from the left: Eluned Morgan, First Minister of Wales

Photo credit: RPS

Invest in pharmacy workforce: RPS Wales urges Senedd members

Members of the Senedd (MSs) were briefed on the increasing pressures facing pharmacy teams and the urgent need for action to support their health and wellbeing at an event hosted by the Royal Pharmaceutical Society (RPS) Wales.

The event, held on Wednesday, brought together MSs, including first minister Eluned Morgan, to discuss the findings of RPS’ latest Workforce Wellbeing Survey.

Keep ReadingShow less
Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less